DOCSLIB.ORG

LOW PRIORITY PROCEDURE: Policy T33 Labiaplasty Author

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LOW PRIORITY PROCEDURE: Policy T33 Labiaplasty Author LOW PRIORITY PROCEDURE: Policy T33 Labiaplasty Author: Ipswich and East and West Suffolk Clinical Commissioning Group First published: July 2011 First revision: April 2014 Second revision: August 2015 Reviewed: July 2016 Review date: July 2018 Policy Summary As with all cosmetic procedures, surgery to alter the appearance of the female genitalia will not be routinely funded by the NHS unless there is a clear clinical need. Patients with a clear clinical indication for labiaplasty will meet one of the criteria detailed in this policy and will be offered surgery. Individual Funding Request* panel will consider requests from clinicians if a patient does not meet the criteria but the clinician feels there is a strong clinical need. *An Individual Funding Request will only be accepted if it is supported by an Obstetrics and Gynaecology Consultant who has performed and documented a clinical examination and confirms that there is a defined clinical need. Eligibility Criteria Patients will be considered for labiaplasty if one or more of the criteria below are met: 1. The presence of another medical condition (such as cancer or congenital malformation) has caused labial hypertrophy and there is clinical indication for labiaplasty. 2. Repair to the labia is required following trauma, including traumatic birth injury. Background to the condition and treatment The term ‘labial hypertrophy’ refers to a state in which the inner labia minora are disproportionately large compared with the outer labia majora. There is no universal definition or measurement for what is ‘normal’ and what is disproportionate and women vary considerably both in the shape and size of their genitalia, and in their perception of normality1. Assessment therefore tends to focus on functionality, for example if a patient finds her labia chafe uncomfortably against her clothes, limit her participation in activities like horse riding or cycling, or interfere with her sexual function2. Labiaplasty is the process of surgically resecting the labia minora in order to reduce their size. The number of labial reduction procedures undertaken by the NHS has increased five-fold over the last decade, and true incidence is probably much higher as no activity data are available for labiaplasties undertaken in the private sector. According to Hospital Evidence Statistics data, 2,000 labiaplasties were undertaken in 2010, however it unknown how many of these were for clinical indications and how many for cosmetic reasons3. Rationale behind the policy The Royal College of Obstetricians and Gynaecologists is of the opinion that there is a lack of high quality evidence supporting the use of labiaplasty and the College reports no data exist on the efficacy of labiaplasty for the treatment of functional problems. Labiaplasty carries the risks of bleeding and wound infection, with wound dehiscence (rupture or splitting open) reported in up to 30% of cases. This can require a second operation to correct. The College also warn of the risk of damage to sensitivity and sexual function following labiaplasty, as surgery can disrupt the nerve supply to the vagina and vulva. The labia minora are thought to play a role in sexual arousal – the area is densely innervated and contains oestrogen receptors and erectile tissue. Removal of this tissue could therefore result in decreased sensation and altered sexual experience. The surgery also carries the risk of scarring, and scar tissue has the potential to disrupt sexual function as the tissues become less contractile3. This stance is mirrored by that of the American College of Obstetrics and gynaecology4. A review of policies by other Clinical Commissioning Groups found eligibility criteria tended to extend only to cancer and congenital malformation and severe trauma, with some CCGs excluding birthing trauma. Media coverage has raised the profile of labiaplasty and increasing numbers of women who are dissatisfied with the appearance of their genitalia are seeking surgery for aesthetic reasons. Issues surrounding gender politics, body dysmorphia and the increasing influence of the porn industry reflect society’s general inclination towards the pursuit of an often distorted view of perfection5-7. The potential explosion of referrals for labiaplasty carries considerable financial implications for the NHS. In order to ensure resources are available to those with real clinical need, Ipswich and East and West Suffolk Clinical Commissioning Group has devised the above criteria which excludes patients seeking labiaplasty for cosmetic reasons. References 1. http://reference.medscape.com/article/1372175-overview#a0102 2. Goodman MP. Female genital cosmetic and plastic surgery: a review. J Sex Med. 2011 Jun;8(6):1813-25 3. http://www.rcog.org.uk/files/rcog-orp/RCOG%20FGCS%20Ethical%20opinion%20paper.pdf 4. ACOG Committee Opinion ‘Vaginal “Rejuvenation” and Cosmetic Vaginal Procedures’, 378, (September 2007). 5. http://www.bbc.co.uk/news/health-18947106 6. http://www.theguardian.com/lifeandstyle/2009/nov/20/cosmetic-vulva-surgery 7. http://blog.wellcome.ac.uk/2012/07/20/new-short-film-centrefold-tackles-the-ethics-of- labiaplasty/ Policies by other CCGs 1. Hull: http://www.hullccg.nhs.uk/data/uploads/clinical-commissioning-policies-from-1-4- 13/new-updated-policies/labiaplasty-and-vaginoplasty-hull-ccg-2014.pdf 2. West Essex: http://www.westessexccg.nhs.uk/Downloads/Your%20NHS/Service%20Restriction%20Polici es/Updated/Labiaplasty%20policy.pdf 3. Warwickshire North: Partially excluded policy. “Labiaplasty of the labia minora for cosmetic or functional reasons is not funded. This policy does not relate to reversal of female genital mutilation which is routinely funded.” 4. Kernow: IFR only. https://www.kernowccg.nhs.uk/media/96960/patient_information__cosmetic_procedures.pdf 5. South Gloucestershire, Bristol, North Somerset: http://www.swcsu.nhs.uk/media/12246/Labiaplasty-Vaginoplasty-and-Hymenorrhaphy- Policy.pdf .
Load more

Recommended publications
  • The Relationship Between Female Genital Aesthetic Perceptions and Gynecological Care
    Examining the Vulva: The Relationship between Female Genital Aesthetic Perceptions and Gynecological Care By Vanessa R. Schick B.A. May 2004, University of Massachusetts, Amherst A Dissertation Submitted to The Faculty of Columbian College of Arts and Sciences of The George Washington University in Partial Satisfaction of the Requirements for the Degree of Doctor of Philosophy January 31, 2010 Dissertation directed by Alyssa N. Zucker Associate Professor of Psychology and Women’s Studies The Columbian College of Arts and Sciences of The George Washington University certifies that Vanessa R. Schick has passed the Final Examination for the degree of Doctor of Philosophy as of August 19, 2009. This is the final and approved form of the dissertation. Examining the Vulva: The Relationship between Female Genital Aesthetic Perceptions and Gynecological Care Vanessa R. Schick Dissertation Research Committee: Alyssa N. Zucker, Associate Professor of Psychology & Women's Studies, Dissertation Director Laina Bay-Cheng, Assistant Professor of Social Work, University at Buffalo, Committee Member Maria-Cecilia Zea, Professor of Psychology, Committee Member ii © Copyright 2009 by Vanessa R. Schick All rights reserved iii Acknowledgments The past five years have changed me and my research path in ways that I could have never imagined. I feel incredibly fortunate for my mentors, colleagues, friends and family who have supported me throughout this journey. First, I would like to start by expressing my sincere appreciation to my phenomenal dissertation committee and all those who made this dissertation possible: Without Alyssa Zucker, my advisor, my journey would have been an entirely different one. Few advisors would allow their students to forge their own research path.
    [Show full text]
  • FGM – Female Genital Mutilation Kvinnlig Könsstympning
    Trollhättan, 17+18/11 2016 Senior FGM – Female Genital Mutilation Kvinnlig Könsstympning Dr. med. Johannes Leidinger, MD., MPH. Senior Consultant in Gynaecology and Obstetrics Överläkare på Kvinnokliniken Södersjukhuset Stockholm & Mälarsjukhuset Eskilstuna Lehrbeauftragter/Dozent der Ludwig-Maximilians-Universität München 16 days of activism 2016 From 25 November, the International Day for the Elimination of Violence against Women, to 10 December, Human Rights Day, the 16 Days of Activism against Gender-Based Violence Campaign is a time to galvanize action to end violence against women and girls around the world. http://www.unwomen.org/en/what-we-do/ending-violence-against-women/ take-action/16-days-of-activism#sthash.zXvSzU8E.dpuf Sexual Violence: ¨ Rape ¨ Indecent Assault ¨ Forced Marriage ¨ Sexual Slavery http://www.eldis.org ¨ FGM (Female Genital Mutilation) ¨ Forced Pregnancy ¨ Forced Abortion ¨ Sexual Harassment WHO: FGM ¨ „FGM comprises all procedures that involve altering or injuring the female genitalia for non­ medical reasons - , and is recognized internationally as a violation of the human rights of girls and women. It reflects deep-rooted inequality between the sexes, and constitutes an extreme form of discrimination against women and girls.“ Program 18 Nov 2016, 9-12 am ¨ Nomenklatur ¨ Klassifikation ¨ Global Prevalens ¨ Förklaringsmodeller ¨ Medicinska komplikationer ¨ Nationell & internationell Lagstiftning ¨ Vård i Sverige – AMEL-mottagning – Operativa rekonstruktioner – Desert Flower Scandinavia ¨ Global perspektiv – Internationella strategier (WHO och NGOs) – Medicalization of FGM Terminology ¨ The expression ”Female Genital Mutilation" gained growing support from the late 1970s. The word ”mutilation” establishes a clear linguistic distinction from male circumcision, and emphasizes the gravity and harm of the act. ¨ In 1990, this term was adopted at the ”3rd Conference of the Inter-African Committee on Traditional Practices Affecting the Health of Women and Children”, in Addis Ababa, Ethiopia.
    [Show full text]
  • GM EUR Generic Funding Request Form NOTE
    2017-19 Effective Use of Resources Treatment Policies GM EUR Team Contacts Tel Email Version 5.7 Funding applications / Process 0161 212 6250 [email protected] List Last Updated 22 January 2019 Policy development 0161 212 6212 [email protected] Approval Funding Approval Category Notes Funding Request Forms Required Individual Funding Request A decision has been taken not to commission a specific treatment. Funding will only be approved if there is evidence of clinical GM EUR Generic Funding Request Form Yes (Exceptional Case) Approval (IFR) exceptional circumstances. NOTE: GM policies have specific funding request forms, please see the end column on the The Commissioner has specifically requested that funding is sought for a particular treatment. The treatment must not be Yes blue coloured rows below. Individual Prior Approval (IPA) undertaken without funding approval from commissioners. Exceptional circumstances do not always have to be demonstrated. PbR Excluded Lists Monitored Approval (MA) The specific treatment may be undertaken in line with agreed EUR policy criteria/routine commissioning arrangements provided the policy criteria is met, clinicians can refer patients without seeking approval. If the patient does not meet the policy NOTE: Only applies if the patient No PbR Excluded Devices List PbR Excluded Drugs List criteria clinicians should apply for Individual Funding Request (Exceptional Case) Approval. Audits may be undertaken to meets the policy critiera. ensure adherence with agreed commissioning arrangements.
    [Show full text]
  • Labiaplasty / Vaginoplasty Commissioning Policy
    Commissioning Statement: Condition or Labiaplasty / Vaginoplasty Treatment: Background: This commissioning policy is needed as cosmetic procedures are not routinely commissioned. Labiaplasty is a surgical procedure where the folds of the labia minora are partially removed, usually for cosmetic reasons alone to change appearance. Non-reconstructive vaginoplasty or "vaginal rejuvenation" is another cosmetic procedure used to restore vaginal tone and appearance Note: Female circumcision is prohibited in law by the Female Genital Mutilation Act 20031 and is the subject of multi-agency guidelines from the Department of Health. Patients who have undergone female genital mutilation should be referred to a specialist female genital mutilation clinic via NHS England. Commissioning The CCG will ONLY routinely commission reconstructive labiaplasty/ position: vaginoplasty: • Following surgery for cancer; • vaginal repair following delivery; • for dyspareunia caused by scarring from vaginal delivery (including Fenton‟s procedure); • for scarring caused by underlying dermatology condition such as Lichen Sclerosis NHS North Yorkshire CCG does not routinely commission labiaplasty/ vaginoplasty, for cosmetic reasons, as these procedures are considered to be of limited clinical value. This is in line with the Interim Clinical Commissioning Policy produced by NHS England. Requests for labiaplasty will be considered, via a request to the IFR Panel, for the following indication: • Where the labia are directly contributing to recurrent disease or infection Requests for vaginoplasty will be considered, via a request to the IFR Panel, for the following indication: • Congenital absence or significant developmental/endocrine abnormalities of the vaginal canal, The clinician needs to submit an application to the CCG‟s Individual Funding Request Panel (IFR) Referral Exceptional cases can be referred to the CCG’s Individual Funding Guidance: Request Panel for prior approval.
    [Show full text]
  • Extensive Vulvar Hematoma As a Complication of Labiaplasty: a Case Report
    Open Journal of Obstetrics and Gynecology, 2020, 10, 880-885 https://www.scirp.org/journal/ojog ISSN Online: 2160-8806 ISSN Print: 2160-8792 Extensive Vulvar Hematoma as a Complication of Labiaplasty: A Case Report Amal Al Mulla*, Humma Habib, Ousama Jarrad OBSGYN & Reproductive Medicine, Amina Hospital, Ajman, United Arab Emirates How to cite this paper: Al Mulla, A., Ha- Abstract bib, H. and Jarrad, O. (2020) Extensive Vul- var Hematoma as a Complication of La- Vulvar hematoma is an extremely rare complication outside obstetric prac- biaplasty: A Case Report. Open Journal of tice. Owing to the vulvar structure and its rich blood supply, hematoma can Obstetrics and Gynecology, 10, 880-885. reach an enormous size over a short period. Although direct trauma is the https://doi.org/10.4236/ojog.2020.1070082 anesthetic 31-year-old nullipara admitted for acute massive vulvar swelling as Received: June 8, 2020 a complication of labiaplasty. She scored 10 on the pain scale. Upon admis- Accepted: July 5, 2020 sion to the emergency department, she had normal vital signs and was imme- Published: July 8, 2020 diately started on intravenous acetaminophen and prophylactic antibiotics. The patient was subsequently transferred to the operating theater for exami- Copyright © 2020 by author(s) and Scientific Research Publishing Inc. nation and drainage of the hematoma under anesthesia. Reconstruction of the This work is licensed under the Creative labia was performed. The patient had a smooth postoperative course and was Commons Attribution International discharged on the 3rd postoperative day. We concluded that Anesthetic gyne- License (CC BY 4.0).
    [Show full text]
  • Redundant Skin Surgery
    Medical Coverage Policy Effective Date ............................................. 6/15/2021 Next Review Date ....................................... 6/15/2022 Coverage Policy Number .................................. 0470 Redundant Skin Surgery Table of Contents Related Coverage Resources Overview .............................................................. 1 Bariatric Surgery and Procedures Coverage Policy ................................................... 1 Blepharoplasty, Reconstructive Eyelid Surgery, and General Background ............................................ 2 Brow Lift Medicare Coverage Determinations .................... 5 Panniculectomy and Abdominoplasty Coding/Billing Information .................................... 5 Surgical Treatments for Lymphedema and Lipedema Treatment of Gender Dysphoria References .......................................................... 6 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description
    [Show full text]
  • The Clinical Role of LASER for Vulvar and Vaginal Treatments in Gynecology and Female Urology: an ICS/ISSVD Best Practice Consensus Document
    Received: 30 November 2018 | Accepted: 3 January 2019 DOI: 10.1002/nau.23931 SOUNDING BOARD The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: An ICS/ISSVD best practice consensus document Mario Preti MD1 | Pedro Vieira-Baptista MD2,3 | Giuseppe Alessandro Digesu PhD4 | Carol Emi Bretschneider MD5 | Margot Damaser PhD5,6,7 | Oktay Demirkesen MD8 | Debra S. Heller MD9 | Naside Mangir MD10,11 | Claudia Marchitelli MD12 | Sherif Mourad MD13 | Micheline Moyal-Barracco MD14 | Sol Peremateu MD12 | Visha Tailor MD4 | TufanTarcanMD15 | EliseJ.B.DeMD16 | Colleen K. Stockdale MD, MS17 1 Department of Obstetrics and Gynecology, University of Torino, Torino, Italy 2 Hospital Lusíadas Porto, Porto, Portugal 3 Lower Genital Tract Unit, Centro Hospitalar de São João, Porto, Portugal 4 Department of Urogynaecology, Imperial College Healthcare, London, UK 5 Center for Urogynecology and Pelvic Reconstructive Surgery, Obstetrics, Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio 6 Glickman Urological and Kidney Institute and Department of Biomedical Engineering Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 7 Advanced Platform Technology Center, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio 8 Faculty of Medicine, Department of Urology, Istanbul University Cerrahpaşa, Istanbul, Turkey 9 Department of Pathology and Laboratory Medicine, Rutgers-New Jersey Medical School, Newark, New Jersey 10 Kroto Research Institute, Department of Material Science and Engineering,
    [Show full text]
  • Gender Reassignment Surgery Model Ncd
    GENDER REASSIGNMENT SURGERY MODEL NCD I. Indications, Limitations of Coverage and/or Medical Necessity 1 II. Documentation Requirements 4 III. Providers of Gender Reassignment Surgery 5 IV. Common CPT Codes 5 V. ICD-9 and ICD-10 Codes 8 VI. References 9 Written by Transgender Medicine Model NCD Working Group. Contact: Anand Kalra, Transgender Law Center ([email protected]). Gender Reassignment Surgery Model NCD | 1 I. Indications, Limitations of Coverage and/or Medical Necessity The purpose of this National Coverage Determination is to implement the U.S. Department of Health and Human Services Departmental Appeals Board’s 2014 decision overturning NCD 140.3 (Transsexual Surgery). The U.S. Department of Health and Human Services Departmental Appeals Board (“DAB”) considered categories of evidence as outlined in the Medicare Integrity Program Manual § 13.7.1 when it determined that the previously extant prohibition on “transsexual surgery” in NCD 140.3 was unreasonable.1 Implementing a policy to provide access to Gender Reassignment Surgery is centered in improving population health outcomes among transgender Medicare beneficiaries. The Medicare Integrity Program Manual § 13.7.1 provides that NCDs should be based on published authoritative evidence and general acceptance by the medical community. Summarized, this means treatments should follow: Evidence-based best practice derived from definitive studies such as meta-analyses, randomized clinical trials, or clinical evidence Best practice as accepted by the medical community, as supported by sound medical evidence based on: o Scientific data or research studies published in peer-reviewed medical journals; o Consensus of expert medical opinion (i.e., recognized authorities in the field); or o Medical opinion derived from consultations with medical associations or other health care experts.
    [Show full text]
  • Gender Dysphoria Treatment – Oxford Clinical Policy
    UnitedHealthcare® Oxford Clinical Policy Gender Dysphoria Treatment Policy Number: SURGERY 103.17 T2 Effective Date: October 1, 2021 Instructions for Use Table of Contents Page Related Policies Coverage Rationale ....................................................................... 1 • Behavioral Health Services Documentation Requirements ...................................................... 3 • Blepharoplasty, Blepharoptosis and Brow Ptosis Definitions ...................................................................................... 3 Repair Prior Authorization Requirements ................................................ 4 • Botulinum Toxins A and B Applicable Codes .......................................................................... 4 • Cosmetic and Reconstructive Procedures Description of Services ................................................................. 5 Benefit Considerations .................................................................. 9 • Gonadotropin Releasing Hormone Analogs Clinical Evidence ......................................................................... 10 • Outpatient Physical and Occupational Therapy U.S. Food and Drug Administration ........................................... 14 (OptumHealth Care Solutions Arrangement) References ................................................................................... 14 • Panniculectomy and Body Contouring Procedures Policy History/Revision Information ........................................... 16 • Physical, Occupational, and Speech Therapy
    [Show full text]
  • 1874-2203/21 Send Orders for Reprints to [email protected]
    1874-2203/21 Send Orders for Reprints to [email protected] 8 Open Medicine Journal Content list available at: https://openmedicinejournal.com CASE REPORT Urinary Retention Secondary to Colpocleisis: A Case Report Elena Soto-Vega1, Yunam Cuan-Baltazar1, Arturo García-Mora2 and Carlos Arroyo1,3,* 1Escuela de medicina, Universidad Anáhuac Puebla, Av Kepler 2143-765, Col. Reserva Territorial Atlixcayotl, Puebla, C.P 72810, México 2Servicio de Urología, Hospital Médica Sur, Mexico City, Mexico 3Servicio de Urología, Hospital Ángeles de Puebla, Puebla, Mexico Abstract: Introduction: Pelvic Organ Prolapse (POP) is common in older women, and depending on its extent, it is conservative or surgically treated. Colpocleisis is a technique for POP treatment, in which the vaginal canal is closed, entirely or partially, in order to avoid the protrusion of the pelvic structures, with preservation of the urethral meatus in order to preserve normal micturition. Clinical Case: We present a case of a 61-year old woman, who 8 years after a colpocleisis, progressed to urinary retention associated with the progressive scarring of the labia, causing the obstruction of the urethral meatus. The patient underwent a labiaplasty with anterior colpoperineoplasty, with complete normalization of her micturition and sexual activity. Conclusion: Long term urinary retention complication has not been previously reported in the literature and should be included as a possible adverse event after colpocleisis. Keywords: Pelvic organ prolapse, Colpocleisis, Urinary
    [Show full text]
  • Dk3608 C000 1..18
    3608_title 7/6/06 9:52 AM Page 1 Anatomy,The Physiology, Vulva and Pathology Edited by MirandaThe Procter & Gamble A. CompanyFarage Cincinnati, Ohio, U.S.A. HowardUniversity of California I. Maibach School of Medicine San Francisco, California, U.S.A. New York London Informa Healthcare USA, Inc. 270 Madison Avenue New York, NY 10016 © 2006 by Informa Healthcare USA, Inc. Informa Healthcare is an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-10: 0-8493-3608-2 (Hardcover) International Standard Book Number-13: 978-0-8493-3608-9 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the conse- quences of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopy- ing, microfilming, and recording, or in any information storage or retrieval system, without writ- ten permission from the publishers. For permission to photocopy or use material electronically from this work, please access www. copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400.
    [Show full text]
  • Clinical Medical Policy
    Clinical Medical Policy Gender Dysphoria Treatment - # 069 Last reviewed: 01 /09/2019 Benefit Coverage Covered Benefit for lines of business including: Health Benefits Exchange (HBE), Rite Care (MED), Children with Special Needs (CSN), Substitute Care (SUB), Rhody Health Partners (RHP), Rhody Health Expansion (RHE), Medicare-Medicaid Plan (MMP) Integrity Excluded from Coverage: Extended Family Planning (EFP) Description The Diagnostic and Statistical Manual-Fifth Edition (DSM V) defines gender dysphoria as follows: “Gender dysphoria refers to the distress that may accompany the incongruence between one’s experienced or expressed gender and one’s assigned gender. Although not all individuals will experience distress as a result of such incongruence, many are distressed if the desired physical interventions by means of hormones and/or surgery are not available.” The World Professional Association for Transgender Health (WPATH) (http://www.wpath.org) is an international, inter-disciplinary organization, which publicizes evidence-based care and clinical guidance in its Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, 7th Version (SOC). SOC is the primary reference for this policy. Individuals, whose birth-assigned gender is male and who have gender dysphoria, are referred to as transwomen. Individuals, whose birth-assigned gender is female and who have gender dysphoria, are referred to as transmen. Coverage Determination Services for Members Less than 18 Years of Age: 1. Behavioral and medical health Services for Members 18 Years of Age and Older: 1. Behavioral and medical health Required 2. Laboratory testing to monitor treatment of gender dysphoria 3. Pharmacological and Hormonal therapy (Prior authorizations unrelated to the treatment of Gender NOT Authorization Dyspshoria may be required.) Services for Members Less than 18 Years of Age: 1.
    [Show full text]